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a b s t r a c t
Medical research on the effects of chemicalwarfare agents (CWAs) has been ongoing for nearly 100 years,
yet these agents continue to pose a serious threat to deployed military forces and civilian populations.
CWAs are extremely toxic, relatively inexpensive, and easy to produce,making thema legitimateweapon
of choice for terrorist organizations.While themechanismsof action formanyCWAshavebeenknown for
years, questions about theirmolecular effects following acute and chronic exposure remain largely unan-
swered. Global approaches that can pinpoint which cellular pathways are altered in response to CWAs
and characterize long-term toxicity have not beenwidely used. Fortunately, innovations in genomics and
proteomics technologies nowallow for thousands of genes andproteins to be identified and subsequently
quantified in a single experiment. Advanced bioinformatics software can also help decipher large-scale
changes observed, leading to mapping of signaling pathways, functional characterization, and identifi-
cation of potential therapeutic targets. Here we present an overview of how genomics and proteomics
technologies have been applied to CWA research and also provide a series of questions focused on how
these techniques could further our understanding of CWA toxicity.
Published by Elsevier Ireland Ltd.
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1. Introduction
Many questions about the medical effects of chemical war-
fare agents (CWAs) remain unanswered even though research on
Abbreviations: CWA, chemicalwarfare agent; SILAC, stable isotope-labelingwith
amino acids in cell culture; ICAT, isotope-coded affinity tags; MS, mass spectrom-
etry; GA, tabun; GB, sarin; GD, soman; GF, cyclosarin; HD, sulfur mustard; CN,
cyanide; BoNT, botulinum neurotoxin; TICs, toxic industrial chemicals; SDS-PAGE,
sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
∗ Corresponding author. Tel.: +1 410 436 6504; fax: +1 410 436 8377.
E-mail addresses: patrick.everley@us.army.mil (P.A. Everley),
james.dillman@us.army.mil (J.F. Dillman 3rd).
CWAs has been ongoing since World War I. As noted by a simple
PubMed search (keywords “genomics” or “proteomics”), the rela-
tively recent development of genomics and proteomics techniques
has resulted in over 50,000 research studies since the 1990 s using
these technologies to understand various biological processes. The
development of microarrays and advances in mass spectrometry
instrumentation now allow for thousands of genes or proteins to
be quantified in a single experiment (Schena et al., 1998; Aebersold
and Mann, 2003). Likewise, these developments also provide
alternative methods of studying CWAs. However, an exhaustive
database search revealeda limitednumberof large-scalegenomics-
and proteomics-related research publications focused on CWAs
(Table 1).
0378-4274/$ – see front matter. Published by Elsevier Ireland Ltd.
doi:10.1016/j.toxlet.2010.08.003
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Table 1
List of systems biology-related genomics and proteomics studies used in CWA
research.
CWA Genomics/proteomics Study
GB Genomics Pachiappan et al. (2009)
Damodaran et al. (2006a)
Damodaran et al. (2006b)
GD Genomics Dillman et al. (2009)
VX Genomics Blanton et al. (2004)
HD Genomics Price et al. (2009)
Gerecke et al. (2009)
Rogers et al. (2008)
Yu et al. (2006)
Dillman et al. (2006)
Dillman et al. (2005)
Rogers et al. (2004)
Shahin et al. (2001)
Lakshmana Rao et al. (1999)
Meier and Millard (1998)
Proteomics Everley and Dillman (2010)
Mehrani et al. (2009)
Mol et al. (2008)
An et al. (2006)
Dillman et al. (2003)
Dillman and Schlager (2003)
Phosgene Genomics Sciuto et al. (2005)
MEDLINE, ToxFile, Biosis Previews, EMBASE and CA SEARCH databases were
searched for articles containing “genomic” or “proteomic” terms using the following
keywords: sarin (GB), soman (GD), VX, VR, sulfur mustard (HD), chlorine, cyanide,
cyclosarin (GF), and phosgene. Articles returned from the database search were fil-
tered for CWA relevance. PubMed was further examined for relevant genomic and
proteomic articles that may have been missed by the original database search.
Given the variety of unanswered questions in the chemical
defense field and the recent use and promise of these technologies
toward other biological applications,we expect a surge in the use of
genomics and proteomics techniques to help us better understand
the molecular toxicology of chemical threat agents. The more we
understand about the effects of CWAs on molecular signaling, cel-
lular function, and organ homeostasis, the better we can advance
the development of medical countermeasures in the event of bat-
tlefield injuries and terrorist attacks. This review article will focus
on the recent use of genomics and proteomics techniques in CWA
research aswell as providediscussion andadditional questions that
these technologies may help us answer.
2. Genomics
Genomics, transcriptomics, and gene expression profiling are
focused on assaying the expression of thousands of genes simul-
taneously in a single biological sample by quantifying the levels
of individual mRNA transcripts. The microarray is the primary tool
used for these studies, with the oligonucleotide microarray (Fodor
et al., 1993) and the cDNA microarray (Schena et al., 1995) being
the most common formats. For oligonucleotide microarrays, the
mRNA extracted from the test tissue is typically amplified using
two in vitro reactions. The mRNA is first reverse transcribed into
cDNA and then transcribed into cRNA. This second reaction utilizes
labeled nucleotides (commonly biotinylated nucleotides), which
are incorporated into the cRNA. The labeled cRNA is thenhybridized
to the oligonucleotides on the microarray and stained with a fluo-
rescent marker. In the case where the nucleotides are labeled with
biotin, the stain is comprised of fluorescently labeled streptavidin,
which binds tightly to the biotin-tagged nucleotides. The fluores-
cent signal is detected bymeans of a laser array scanner. The levels
of fluorescence of the experimental sample on one microarray are
compared to those of the control sample on another microarray to
determine which genes are up- and down-regulated.
For cDNA microarrays, the control sample and the experimen-
tal sample are labeled separately with different fluorescent dyes
(e.g., Cy3 and Cy5), pooled together in equal amounts, and
hybridized to the same microarray. The fluorescent signal is
detected using a confocal laser scanner with dual fluorescence
capability. The ratio of the two fluorescent dyes at each cDNA spot
on the microarray is used to calculate the level of expression of
each gene in the study and determine which genes are up- and
down-regulated.
The field of toxicology has exploited the potential of microar-
rays to help elucidate molecular mechanisms of chemical toxicity.
Microarrays are used to characterize changes in gene expression
due to a toxicant of interest, identify genes up- or down-regulated,
map regulatory pathways modulated by the toxicant, and, in
the case of CWAs, identify potential therapeutic targets in these
pathways (Thomas et al., 2001; Hamadeh et al., 2002). In addi-
tion, microarrays can be used to examine the role of microRNA
(miRNA) in chemical toxicity. miRNAs are short, single-stranded
RNA sequences that regulate gene expression by binding to the reg-
ulatory regions of mRNA and preventing translation, representing
another mechanism of regulating gene expression besides up- or
down-regulation of transcription (Fabian et al., 2010). Thepotential
role of miRNA in CWA toxicity has not been explored.
3. Genomics applications to CWAs
Early work by Damodaran et al. suggested differential distri-
bution of acetylcholinesterase (Damodaran et al., 2003) and alpha
tubulin (Damodaran et al., 2002) mRNA expression levels in differ-
ent regions of the rat brain following exposure to the nerve agent
sarin (GB). While these targeted mRNA studies were restricted to
only a limited set of genes, they paved theway for additional large-
scale genomics analyses of GB-induced toxicity.
Consequently, Damodaran and coworkers used genomic
microarrays to explore both early (15min, 0.5× LD50) and late
(3 month, 1× LD50) time points following GB exposure in the rat
brain (Damodaran et al., 2006b). While this work identified many
genomic alterations unique to each time point, seven genes were
identified thatwereconsistently altered inboth timepoints, includ-
ing Ania-9, Arrb-1, CX-3C, Gabab-1d, Nos-2a, Nrxn-1b, and PDE2.
Further genomic studies by their group showed that following
acute GB exposure, several gene categories –most notably those of
ion channels and those of calcium channel and binding proteins –
were identified in the rat brain as significantly altered (Damodaran
et al., 2006a). Thisworkwent on toprovide additional evidence that
both degenerative and regenerative pathways are activated early
after GB exposure. More recently, Pachiappan and colleagues used
human neuronal cells (SH-SY5Y) exposed to low-dose GB to fur-
ther explore neurodegeneration signaling (Pachiappan et al., 2009).
Using microarrays, they identified over 200 genes significantly
dysregulated following GB administration, and subsequent bioin-
formatics analysis characterized the ETS2-regulatedmitochondrial
death pathway as the main neurodegenerative signaling pathway
activated in response to GB. It should be noted that this study was
performed using a cell line and thus the gene expression profiles
represent the response of a single cell type. This is in contrast to
the study using brain tissue, which represents multiple cell types
and thus the gene expression profiles represent a tissue response
rather than the response of a single cell type. This is often the case
in in vivo microarray studies in which an organ or tissue is isolated
for microarray analysis.
A comparison of these studies reveals several similarities. Both
Damodaran studies showed significant alterations in the following
gene categories: those of calcium channel and binding proteins and
those of cytoskeletal and cell adhesion molecules (Damodaran et
al., 2006a,b). Furthermore, these two studies along with the Pachi-
appan study (Pachiappan et al., 2009) all showed dysregulation
of mitochondrial-associated genes, including several Bcl-2-related
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genes. Future genomics methods could be employed to identify
additional mitochondrial genes involved, expand on any parallel
pathways, and to further delineate the roles these genes play in
GB-induced neuronal toxicity.
Soman (GD) is another extremely toxic nerve agent that inhibits
acetylcholinesterase. While the mechanism of action is similar to
other nerve agents, GD presents a unique problem in that inter-
ventional treatment must occur immediately after exposure due
to a secondary reaction that results in dealkylation of the nerve
agent adduct (“aging”) (Loomis and Johnson, 1966). Accordingly,
are there downstream signaling changes and long-term effects of
this agent following acute exposure that may differ from those of
GB? Is the mechanism of neurodegeneration similar to that caused
by other nerve agents? Work by our group and coworkers profiled
gene expression changes in rat hippocampus following GD expo-
sure to gain insight into themolecular pathogenesis of GD-induced
neurodegeneration (Dillman et al., 2009). Results showed numer-
ous signalingmechanisms – particularly inflammatory pathways –
perturbed following exposure. Many of these perturbations were
still present one week post-exposure, indicating several mecha-
nisms for future follow-up to determine their role in GD-induced
neurodegeneration.
While the genomics studies performed to date have provided
a wealth of information on nerve agent-induced toxicity, an accu-
rate comparison of agents to draw valuable conclusions is difficult
due to differences in exposure paradigms between the studies. Is it
possible that the differences observed between GB and GD at the
genomic level are due to variations in the doses of agents used in
each study? Can pretreatments and therapeutics impact the long-
termeffects of agent exposure ongene expression?To compare and
contrast differences between the long-term effects of agent neu-
rotoxicity, future work should focus on using the same exposure
paradigm for each agent. For example, an attempt should be made
to provide standardization of agent exposure route (e.g. inhalation
aswell as intramuscular, intraperitoneal, percutaneous, and subcu-
taneous injections), dose, exposure time points, and similar types
of prophylactics and therapeutics. Only under these controlled con-
ditions can we accurately draw comparisons between large-scale
signaling changes observed at the genomic level for different nerve
agents.
Genomicsmay also shed light on some additional poorly under-
stood toxic effects of nerve agents. For instance, it has been noted
that civilians exposed to industrial organophosphates such as pes-
ticides have a higher incidence of Parkinson’s disease (Hatcher
et al., 2008; Manthripragada et al., 2010), but it is unknown if
nerve agents lead to the same neurodegenerative effects. Acute
effects of nerve agents include neuroinflammation (Svensson et
al., 2001; Williams et al., 2003; Chapman et al., 2006; Dhote et
al., 2007; Dillman et al., 2009), but does this neuroinflammation
diminish across time? Are long-term regional differences observed
in the brain following nerve agent exposure reflected in large-scale
gene expression changes, and can this information be used to cor-
relate gene expression profiles with altered behavioral patterns?
Genomics studies can be expanded to answer these questions and
provide additional information aswe come to understand themyr-
iad of chronic effects of nerve agent exposure.
Large-scale genomics have also been applied to blistering agents
such as sulfur mustard (HD). HD causes DNA damage and acti-
vates numerous signaling cascades upon exposure, most of which
are poorly understood with respect to their role in HD-induced
vesication. Thus, one clear benefit of microarray analysis is the
potential to identify thousands of genes dysregulated in response
to HD and, using mapping software, to characterize significantly
altered pathways. Early microarray studies identified pathways
such as inflammation, apoptosis, protein catabolism, and cell cycle
as involved in HD-induced toxicity (Rogers et al., 2004; Dillman
et al., 2005). Likewise, genomics efforts from our group are now
focused on assessing how HD exposure dose and time affect these
signaling pathways.
HD is known to cause serious cutaneous damage, but the
mechanism by which this occurs at the molecular level is poorly
understood. Since similar therapies have historically been used to
treat thermal and HD burns, recent microarray work assessed sim-
ilarities and differences between thermal- and HD-induced skin
injuries (Rogers et al., 2008; Price et al., 2009). Gene expression pat-
terns identifiedpotential therapeutic targets forwoundhealingand
a significant overlap in inflammatorymechanisms. For example, IL-
6, IL-10, and p38 MAPK canonical signaling pathways increased in
both HD and thermal burn models (Price et al., 2009), suggesting
that pharmacologic and biologicmodulators that target these path-
ways and that are currently in development for treating thermal
burns may also be used to treat HD injuries. However, are there
any etiological differences between thermal and HD burns such
that treatment regimens for these two classes of injury may not
overlap? Differences observed between thermal- and HD-induced
injuries may point toward additional therapeutic targets following
HD exposure.
4. Proteomics
Despite the potential of microarray approaches to assist in
understanding toxicant mechanisms, their primary limitation lies
in the fact that theycanonlyassess geneexpressionchanges. Effects
due to changes in protein expression, modification, or function can
only be inferred from this approach and not directly observed or
measured. To assess protein expression status, techniques from the
field of proteomics must be used.
Two-dimensional SDS-PAGE (2D-PAGE) has been vital to early
proteomics studies. Using gels, proteins collected from cell lysates
or tissues can be resolved in a two-dimensionalmatrix and, follow-
ing staining, their intensities canbe compared todetermine relative
abundance between samples. Due to the high variation between
gels, 2D difference gel electrophoresis (2D-DIGE) has emerged to
allow for different protein samples to be resolved and quantified on
a single gel (Alban et al., 2003). Alternatively, protein arrays (e.g.
ligand- and antibody-based arrays) also offer a means for large-
scale differential analysis of proteins from complex mixtures and
have already been used in protein expression monitoring, drug
target discovery, and biomarker identification (Tao et al., 2007).
Regardless of gel or array analysis used, qualitative information
for proteins (i.e. identification) is most easily provided by mass
spectrometry (MS) to further characterize changes in abundance.
The introduction of faster and more sensitive MS instrumenta-
tionhas led to advances inprotein identification technologies. Early
protein identificationmethods such as Edman degradation took up
to 10hours to sequence a single peptide. With MS, high-quality
sequence information for that same peptide can be obtained in less
than a second. Combining liquid chromatography with MS-based
analyses of complex mixtures also overcomes many of the draw-
backs to gel-based methods, such as limited dynamic range and
sensitivity, as well as low throughput with respect to protein iden-
tification (Peng and Gygi, 2001). The addition of stable isotopes to
the proteome via metabolic and chemical labeling strategies has
further empoweredMS by allowing for simultaneous protein iden-
tification and highly accurate quantitation.
Metabolic and chemical labeling of the proteome with stable
isotopes are most commonly used in conjunction with MS (Fig. 1).
A popular and effective method of metabolic labeling is stable
isotope-labelingwith amino acids in cell culture (SILAC) (Ong et al.,
2002). Briefly, amino acids containing either 12C14N or 13C15N are
added to the growthmedium for cultured cells. Several population
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Fig. 1. Examples of common isotopic labeling strategies for use in quantitative proteomics studies. Themain difference betweenmetabolic and chemical labeling studies is the
time at which labeling occurs. Inmetabolic labeling experiments, stable isotope-containing amino acids are added during cell culture and therefore incorporated directly into
theproteome. In chemical labeling experiments, stable isotope-containing chemical tags are added after protein samples are collected. Regardless of labeling strategy, samples
are combined after the labeling step at equal ratios and processed as a single sample, thus reducing variations in sample handling. After additional fractionation/enrichments
steps to reduce mixture complexity and increase sensitivity, samples are proteolytically digested and processed for mass spectrometry (LC–MS/MS), which results in protein
identification and quantitation. Red and blue denote isotopically “light” and “heavy” samples/peptides, respectively. Note: depending on the type of enrichment strategy
used (peptide vs. protein), the fractionation/enrichment step may occur after sample digestion.
doublings allow full proteome incorporation, giving rise to isotopi-
cally “light” and “heavy” cellular proteomes. In contrast, chemical
labeling strategies such as isotope-coded affinity tags (ICAT) (Gygi
et al., 1999a) are performed after protein is collected. The basic
concept is the same in that two distinct cell populations are dif-
ferentially labeled with 12C14N and 13C15N isotopes (in this case,
affinity tags that covalently bind to cysteine residues), again giving
rise to isotopically light and heavy cellular proteomes. Regardless
of the typeof isotopic labeling strategyused, proteins are then com-
bined at a 1:1 ratio and processed together so that any variability
in sample processingwill be drasticallyminimized. Samples can be
further fractionated prior to proteolytic digestion to reduce mix-
ture complexity and increase sensitivity in protein identification.
Dependingon the typeof analysis, additional enrichment strategies
can be used, such as those that isolate post-translational modifica-
tions. Finally, samples are analyzed using MS and bioinformatics
programs that will yield protein identification and quantitation.
See review article by Ong and Mann for additional information on
quantitative MS (Ong and Mann, 2005).
5. Proteomics applications to CWAs
As shown in Table 1, very few studies have used proteomics
approaches in CWA research. These techniques represent an
untapped resource for the field since the majority of cellular
functions are carried out at the protein level. Some studies have
suggested that mRNA and protein levels do not always correlate
(Gygi et al., 1999b; Ahram et al., 2002), further strengthening the
argument for using proteomics. In fact, this RNA/protein discon-
nect could be relevant in CWA research. For example, Blanton and
colleagues suggested that their inability to discern any perma-
nent gene expression changes following twoweeks of low-dose VX
exposure could have been due to more sustained up-regulation of
protein levels (Blanton et al., 2004). In addition, post-translational
modifications suchasphosphorylationare important invarious cel-
lular processes, with several MS-based techniques uniquely suited
to carry out this analysis.
Early work focused on the use of gel-based methods to iden-
tify proteins involved in HD toxicity. Cultured keratinocytes were
used as a model system to identify keratin aggregates found
to crosslink with each other following HD exposure, with high-
molecularweight aggregates forming in as little as 15min (Dillman
et al., 2003). Additional studies used 2D-PAGE and MS to investi-
gate large-scale protein changes after HD exposure (Dillman and
Schlager, 2003; An et al., 2006; Mol et al., 2008). Specifically,
Mol and colleagues exposed human keratinocytes to 14C-labeled
HD (100M), resolved and visualized protein lysates with 2D
gels and autoradiography, and used MS to identify proteins that
formed adducts with HD (Mol et al., 2008). The identification
of numerous cytokeratins, actin, stratifin, and galectin-7 in their
study indicated that HD may alter cellular architecture, suggest-
ing a possible role of the cytoskeleton for the onset of vesication.
To further determine the role of these cytoskeletal proteins in
vesication, future quantitative proteomics studies could focus on
whether any of these are up- or down-regulated following HD
exposure.
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An and coworkers also used 2D-PAGE to analyze differential
protein expression from control vs. HD-exposed (5L, 160g/L)
mouse ears (An et al., 2006). Complementing the Mol et al. study
noted above, their results showed dysregulated expression of sev-
eral cytoskeletal proteins, such as actin, destrin, and profilin-1.
Furthermore, their results showed dysregulated expression of pro-
teins involved in oxidative stress responses, apoptosis, and energy
metabolism, suggesting additional pathways for future follow-up.
More recent studies by our group have incorporated the use of
SILAC and phosphorylation enrichment, leading to the identifica-
tion and quantitation of over 2300 phosphopeptides from HaCaT
cells exposed to HD (200M) (Everley and Dillman, 2010). The
NFB and caspase pathways were identified in this study and have
already been shown to play a role in HD toxicity (Ruff and Dillman,
2007), but many additional proteins not implicated in previous HD
studies were also identified. These include DPF2 (a predicted tran-
scription factor involved in apoptosis), ZMYND8 (a protein known
tobephosphorylateduponDNAdamage), andBCLAF1 (aBcl-2 tran-
scription factor involved in apoptosis), among others (Everley and
Dillman, 2010). Determining the extent that these proteins play in
HD-induced vesication and their impacts on signaling will be the
topic of future work.
Even with recent proteomics work on HD, many of the molec-
ular changes following exposure are still poorly understood. We
observe numerous protein changes following agent exposure, but
future studies should determine how many of these proteins have
a direct role in vesication and how many are simply altered as
downstream effects. We have shown that protein phosphorylation
is altered on a large-scale early after exposure, but canwemine our
current proteomics datasets and expand the scope of these stud-
ies to identify additional kinases activated in response to HD that
may serve as effective therapeutic targets? Bioinformatics software
programs such as Ingenuity Pathway Analysis (Ingenuity Systems,
Inc., Redwood City, CA) are vital to mining large-scale datasets and
will prove to be even more valuable with the continued expansion
of MS-based technologies, with a goal of providing a more global
characterization of the proteome.
Multiplex-labeling proteomics strategies such as iTRAQ (Ross
et al., 2004) have also gained prominence in recent years and now
allow up to eight different samples to be simultaneously character-
ized using MS. Instead of usingWestern blots to analyze a series of
pre-selected proteins for time-course studies, iTRAQ and MS could
be used to assess hundreds or even thousands of proteins and how
their levels change following different HD exposure times, all in
a single experiment. iTRAQ and ICAT can also be applied to the
analysis of tissues from HD-exposed animal models to discover
and understand in vivo changes on a large-scale. We are confi-
dent that further insight will be gained as proteomics technologies
mature, giving researchers the potential to characterize additional
proteins and piece together signaling pathways that play a role in
HD-induced toxicity.
6. Other agents of interest
This reviewhas focusedonnerveandblister agents, but thereare
numerous other classes of chemical threats forwhich genomics and
proteomics analyses could be helpful. For example, toxic industrial
chemicals (TICs) pose a unique risk due to their ease of produc-
tion and acquisition, and their acute toxicity. This class includes
bromine (Sagi et al., 1985), chlorine (Squadrito et al., 2010), cyanide
(Baskin and Rockwood, 2002), carbonyl chloride (phosgene) (Borak
andDiller, 2000), and pesticides such as parathion and chlorpyrifos
(Ballantyne and Marrs, 1992).
OneTICofparticular concern is cyanide (CN), anextremely lethal
blood agent that is easy and inexpensive to produce (Baskin and
Rockwood, 2002). The effects of CN can appear within seconds of
exposure and particularly affect the heart and brain. Early treat-
ments with nitrites are effective but can produce central nervous
system side effects, such as altered motor function and learning
behaviors.However, anattempt tounderstand these long-termside
effects at the molecular level in different regions of the brain has
not been undertaken. This knowledge gap could be addressed by
the use of genomics and/or proteomics technologies to determine
themolecular effects of variousCNexposure therapies,which could
in turn shed light on which therapies are most effective with the
fewest long-term side effects.
Another TIC of concern is phosgene, which is widely used in
industry for the production of synthetic products and which, if
inhaled, can cause pulmonary edema and irreversible lung injury
(Sciuto et al., 2005). Microarray analysis showed that one of the
most significantly altered genes is glutamate cysteine ligase (GCL)
catalytic subunit, the rate-limiting enzyme in the synthesis of glu-
tathione. These results were cross-validatedwith biochemical data
from a previous study (Sciuto et al., 2003), confirming the biologi-
cal significance of this result. Furthermore, other genes involved
in glutathione synthesis and maintenance of cellular redox sta-
tus were significantly increased, indicating a molecular response
consistent with oxidative stress. These results provide the basis
for pursuing therapeutic strategies that target redox systems in
the lung as a medical countermeasure for chemically induced lung
injury.
Aside from TICs, other chemicals of biological origin pose simi-
lar threats as CWAs. Among these is botulinum neurotoxin (BoNT),
a 150kDa protein that blocks acetylcholine release from neurons
and can eventually cause severe paralysis and death if introduced
at high enough doses (Simpson, 2004). BoNT intoxication renders
neurons incapable of communication with muscle cells, eventu-
ally resulting in changes in cell morphology (Meunier et al., 2003).
Since this in turn suggests changes in cell signaling, what are the
transcriptional and translational pathways activated in response to
this blockade? Do they influence long-term resumption of synap-
tic activity? Current genomic and proteomic studies are ongoing
at USAMRICD to help answer these questions and others. The fact
that BoNT is one of the most lethal substances known – the LD50
(ng/kg) is over 1000-fold lower than that of VX – underscores
the importance of understanding both its short- and long-term
effects.
7. Conclusions
Transcriptomics-related CWA research over the past several
years has spanned a variety of chemical threats. This work has pro-
vided insight into mechanisms of acute vesicant toxicity and also
mechanisms of nerve agent-induced brain injury. In addition, work
withphosgenehas revealedpotential therapeutic strategies to treat
chemically induced lung injury.
Proteomics-related CWA research has been predominantly
focused on HD. Surprisingly, large-scale proteomics studies using
nerve agents have been lacking. Just as microarrays have been
used to map signaling networks for GB and GD, proteomics stud-
ies could also complement and expand on that work to identify
additional signaling pathways impacting agent toxicity. Further-
more, genomics and proteomics could be applied to the remaining
nerve agents, such as cyclosarin (GF) and VR, to determine if these
agents have similar long-termeffects at themolecular level as other
agents.
CWAs have been a threat sinceWWI and continue to be a threat
today. Medical research on these agents has led to treatments to
improve survivability, but many questions remain with respect to
mechanismsof toxicityat themolecular level.Weareconfident that
as technologies improve and techniques become more common-
place, the use of genomics and proteomics will further accelerate
302 P.A. Everley, J.F. Dillman, 3rd / Toxicology Letters 198 (2010) 297–303
our understanding of CWA toxicity and ultimately lead to the iden-
tification of candidate pathways for better targeted therapeutic
intervention.
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